Febuxostat Pharmacokinetics, Efficacy and Tolerability in Hemodialysis Patients with Hyperuricemia - Febuxostat Pharmacokinetics, Efficacy and Tolerability in Hemodialysis Patients with Hyperuricemia

Teikyo University School of Medicine0 个研究点目标入组 8 人开始时间: 2013年4月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet any of the following criteria will be excluded from the study: 1. Patients who present with gouty arthritis at the time of the examination before entry or at entry, or those in whom gouty arthritis had resolved only 2 weeks or sooner before entry 2. Patients who received drugs that must not be used within 2 weeks before entry 3. Patients complicated with any of the following diseases at entry: (i) Lesch-Nyhan syndrome [deficiency of hypoxanthine-phosphoribosyltransferase (HPRT)], (ii) elevated 5-phosphoribosyl-1-pyrophosphatase (PRPPase), (iii) congenital myogenic hyperuricemia, (iv) psoriasis vulgaris, (v) hemolytic anemia, (vi) hypothyroidism, (vii) rhabdomyolysis, (viii) glycogenosis I (due to lactic acidemia), (ix) toxemia of pregnancy, (x) polycystic kidney disease, (xi) lead nephropathy, (xii) Down syndrome, (xiii) sarcoidosis 4. Patients with liver damage (ALT >= 100 IU/L) 5. Patients with a history of hypersensitivity to febuxostat preparations 6. Patients who are or may be pregnant or breast-feeding 7. Patients receiving mercaptopurine hydrate or azathioprine 8. Other patients judged by the investigator to be ineligible for entry into the study

发起方

Teikyo University School of Medicine